Can Remote Photoplethysmography Be Used for Contactless Vital Sign

Status Not yet recruiting

Clinical Trial Summary

Contactless and widely available health monitoring technologies are of growing interest in the context of the worldwide COVID-19 pandemic. Remote photoplethysmography (rPPG) is a well-studied technology that interprets variations in skin colour related to blood flow which, when analysed with complex mathematical algorithm, generates vital sign readings. This technology has been refined and embedded in a smartphone app designed to acquire heart rate, respiratory rate and oxygen saturation using a front-facing smartphone camera.

Preliminary data comparing the accuracy of smartphone rPPG readings with conventional vital sign monitor readings are promising; however, less than 5% of the population studied in the app development phase had oxygen saturation levels below 95% making it impossible to ensure reliability in these populations.

The goal of this study is to compare readings acquired using this rPPG app with the readings from hospital grade, Health Canada approved vital signs monitors used in healthcare settings with a focus on subject with low oxygen saturations. We will also study other sociodemographic and clinical features that may influence the accuracy of the readings. This will be achieved by recruiting consenting adults presenting to care in acute care settings and a designated COVID outpatient clinic. Vital signs will be acquired using the rPPG app and conventional hospital vital sign monitors simultaneously. Readings will be repeated within 2-5 minutes when time permits. Statistical analysis will be performed to analyze the findings and determine the accuracy and precision of the rPPG app readings.

It is expected that the vital sign readings acquired with the rPPG app will be almost identical to those acquired using hospital-grade monitors for all subjects regardless of age, gender, skin colour, COVID status and relevant comorbidities.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04489407
Study type	Interventional
Source	Lady Davis Institute
Contact	Noura Hassan, MD, MPH
Phone	514-340-8222
Email	noura.hassan@mcgill.ca
Status	Not yet recruiting
Phase	N/A
Start date	August 1, 2020
Completion date	November 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05971407` - The Effect of Chronic Remote Ischaemic Preconditioning on Blood Pressure in Older Adults	N/A
Enrolling by invitation	`NCT03683186` - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension	Phase 3
Recruiting	`NCT04584632` - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery	N/A
Recruiting	`NCT04390672` - Multivessel TALENT	N/A
Completed	`NCT01915368` - Determining Optimal Post-Stroke Exercise (DOSE)	N/A
Completed	`NCT01684826` - X-ray Dose Reduction Study for Cardiac Angiography and Intervention	N/A
Completed	`NCT01417910` - Predictors of Post Operative Outcome in Peripheral Vascular Surgical Patients	N/A
Terminated	`NCT00935766` - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries	Phase 3
Unknown status	`NCT01748383` - The Long-term and Short-term Efficacy and Safety of Transplantation Autologous Bone Marrow Cells (BMCs) in Patients With the First STEMI (ST Segment Elevation Myocardial Infarction)	Phase 2
Recruiting	`NCT05907564` - Aventus Thrombectomy System Pulmonary Embolism Clinical Study	N/A
Recruiting	`NCT03732612` - Inflammation in Vascular Disease
Completed	`NCT00000614` - Prevention of Recurrent Venous Thromboembolism (PREVENT)	Phase 3
Completed	`NCT00000479` - Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer	Phase 3
Completed	`NCT00000530` - Raynaud's Treatment Study (RTS)	Phase 3
Completed	`NCT00000539` - Arterial Disease Multifactorial Intervention Trial (ADMIT)	Phase 3
Completed	`NCT00000474` - Prevention and Treatment of Hypertension Study (PATHS)	Phase 3
Completed	`NCT00000528` - Trials of Hypertension Prevention (TOHP)	Phase 3
Completed	`NCT00000509` - Potassium and Sodium to Control Blood Pressure in Hypertensives	Phase 3
Completed	`NCT00000501` - Hypertension Prevention Trial (HPT) Feasibility Study	Phase 2
Completed	`NCT00000499` - Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Can Remote Photoplethysmography Be Used for Contactless Vital Sign Acquisition in a Healthcare Setting? A Prospective Comparative Study.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms